May 2, 2013 - ZOLL LifeVest Wearable Defibrillator To Be Showcased at SCAI 2013

MEDIA CONTACT:  

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com  

 

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT SCAI 2013

 

May 2, 2013—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that that it will highlight the LifeVest® Wearable Defibrillator in Booth #1201 at the 2013 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions, May 8-11 at The Peabody Hotel in Orlando.

The LifeVest will be discussed during a satellite symposium on Friday, May 10 at 12 p.m. at The Peabody Hotel in Bayhill Rooms 17-18:

  • James B. Hermiller, MD, St. Vincent Hospital, Indianapolis, will present “Identifying the Risk: Sudden Cardiac Death and the Post-AMI Patient.”
  • Jack P. Chen, MD, Northside Hospital, Atlanta, will present a “Staged-PCI Case Study.”

The LifeVest protects patients at risk for sudden cardiac death. It is used to protect a wide range of patients, including recent myocardial infarction, or following coronary revascularization. Following a percutaneous coronary intervention (PCI), procedure, 1 in 5 patients have been shown to be at high risk of early mortality.1 In post-PCI patients with a low ejection fraction (≤35%), three-month mortality is 13%2, and increases significantly in the presence of other risk factors3. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden cardiac death.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from sudden cardiac arrest. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

©2013 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.

1 Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397–1405.
2 Zishiri E, et al. Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction. Circulation 2011; 124:A9816.
3 Weintraub et al. Prediction of Long-Term Mortality After Percutaneous Coronary Intervention in Older Adults: Results From the National Cardiovascular Data Registry. Circulation 2012;125:1501–1510.